In a phase 3 clinical trial, the NGF‐targeting monoclonal antibody, tanezumab, demonstrated significant analgesic efficacy for bone metastasis‐related pain, indicating its potential as a novel therapeutic option for cancer pain management [198]. This evidence concerns the gene NGF and cancer.